Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Evaxion A/S announced promising phase 2 trial data for its personalized cancer vaccine EVX-01, designed with its AI-Immunology™ platform, showing an 86% success rate in vaccine targets eliciting tumor-specific immune responses. The data, presented at the AACR Annual Meeting, reinforce the platform's capability to select relevant vaccine targets and…